Drugmakers encouraged doctors to prescribe these drugs for children before the FDA sanctioned their use for youngsters. This was particularly troubling, given that the drugs can cause diabetes and weight gain, side effects that prompted thousands of lawsuits claiming that drugmakers tried to hide evidence of these problems.
Clearly the drug industry needs New Year’s Resolutions–and to honor them better than the Corporate Integrity Agreements with the government it keeps breaking. How about: “We will stop upgrading anxiety to depression, depression to bipolar disorder and bipolar disorder to ‘treatment resistant depression’ to sell drugs. We will admit that studies are beginning to show that the reason depression is sometimes treatment resistant is because it wasn’t depression to begin with but consumer advertising.”
Study patients took the anti-seizure drug Neurontin, and researchers measured tons of possible outcomes (like pain with touch, pain with cold, excessive pain with pinpricks, more than a dozen different scales for psychiatric symptoms, and so on). By random chance, if you measure enough outcomes, at least some of them will appear better after drug treatment. When the time came to report the findings, however, the researchers systematically omitted the outcomes on which the drug had no effect—and presented only the data showing benefit. That’s like dealing dozens of hands of poker to yourself but showing only the hand with good cards.
The Texas Medication Algorithm (flow chart) Project (TMAP) was developed in 1995 in a collaborative effort between the pharmaceutical industry, prominent University of Texas psychiatrists…
Prescriptions for psychiatric drugs increased 50 percent with children in the US, and 73 percent among adults, from 1996 to 2006, according to a study in the May/June 2009 issue of the journal Health Affairs. The CIA “World Factbook” estimate the world population to be about 6.8 billion and the US population to be a mere 307 million. In an April 2008 report, the market research firm Datamonitor reported that the “US dominates the ADHD market with a 94 percent market share.”